(RELX) Relx - Overview
Sector: Industrials | Industry: Specialty Business Services | Exchange: NYSE (USA) | Market Cap: 57.386m USD | Total Return: -36.7% in 12m
Data Analytics, Academic Journals, Legal Research, Trade Shows
Total Rating 46
Safety 55
Buy Signal -0.22
Specialty Business Services
Industry Rotation: +3.2
Industry Rotation: +3.2
Market Cap:
57.4B
Avg Turnover: 87.7M
Avg Turnover: 87.7M
Risk 3d forecast
Volatility27.3%
VaR 5th Pctl4.88%
VaR vs Median8.48%
Reward TTM
Sharpe Ratio-1.53
Rel. Str. IBD18.6
Rel. Str. Peer Group48.1
Character TTM
Beta0.468
Beta Downside0.595
Hurst Exponent0.676
Drawdowns 3y
Max DD49.91%
CAGR/Max DD0.11
CAGR/Mean DD0.57
Warnings
Altman Z'' 1.09 < 1.0 - financial distress zone
Overextended 3d
Tailwinds
No distinct edge detected
Description: RELX Relx
RELX PLC is a London-based global provider of information-based analytics and decision tools serving professional and business clients. The company operates through four distinct segments: Risk, Scientific, Technical & Medical (STM), Legal, and Exhibitions. Its business model focuses on transforming raw data into actionable insights through proprietary algorithms and technology, facilitating risk assessment, scientific research, and legal compliance.
The company transitioned from a traditional publisher to a data analytics firm, a shift common within the Research & Consulting Services sub-industry to secure recurring subscription revenue. RELX serves a diverse geographical footprint, with significant operations in North America and Europe, leveraging high-barrier-to-entry datasets. Investors can examine further financial metrics and valuation trends for RELX on ValueRay.
The Risk segment utilizes public and industry-specific content to predict outcomes, while the STM and Legal divisions provide specialized databases for academic and regulatory professionals. The Exhibitions segment integrates digital lead-generation tools with physical events to facilitate B2B transactions.
- AI-driven analytics expansion accelerates high-margin revenue growth in Risk and Legal segments
- Open access publishing transition impacts subscription margins within Scientific and Medical division
- Global corporate marketing budgets dictate cyclical recovery and profitability of Exhibitions segment
- Regulatory scrutiny of data privacy practices poses operational risks to information services
Piotroski VR‑10 (Strict)
8.0
| Net Income: 3.99b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.37 > 0.02 and ΔFCF/TA 16.54 > 1.0 |
| NWC/Revenue: -15.94% < 20% (prev -18.93%; Δ 2.99% < -1%) |
| CFO/TA 0.37 > 3% & CFO 5.51b > Net Income 3.99b |
| Net Debt (7.19b) to EBITDA (6.07b): 1.18 < 3 |
| Current Ratio: 0.49 > 1.5 & < 3 |
| Outstanding Shares: last quarter (1.83b) vs 12m ago -3.31% < -2% |
| Gross Margin: 65.00% > 18% (prev 0.62%; Δ 6.44k% > 0.5%) |
| Asset Turnover: 128.1% > 50% (prev 92.14%; Δ 35.99% > 0%) |
| Interest Coverage Ratio: 7.71 > 6 (EBITDA TTM 6.07b / Interest Expense TTM 568.5m) |
Altman Z''
1.09
| A: -0.21 (Total Current Assets 2.95b - Total Current Liabilities 5.98b) / Total Assets 14.73b |
| B: 0.13 (Retained Earnings 1.89b / Total Assets 14.73b) |
| C: 0.30 (EBIT TTM 4.38b / Avg Total Assets 14.82b) |
| D: 0.03 (Book Value of Equity 392.3m / Total Liabilities 12.35b) |
| Altman-Z'' Score: 1.09 = BB |
Beneish M
-3.10
| DSRI: 0.77 (Receivables 2.46b/2.32b, Revenue 18.99b/13.74b) |
| GMI: 0.95 (GM 65.00% / 61.53%) |
| AQI: 0.99 (AQ_t 0.79 / AQ_t-1 0.79) |
| SGI: 1.38 (Revenue 18.99b / 13.74b) |
| TATA: -0.10 (NI 3.99b - CFO 5.51b) / TA 14.73b) |
| Beneish M-Score: -3.10 (Cap -4..+1) = AA |
What is the price of RELX shares?
As of May 19, 2026, the stock is trading at USD 33.96 with a total of 2,388,606 shares traded.
Over the past week, the price has changed by +2.07%, over one month by -5.76%, over three months by +13.34% and over the past year by -36.74%.
Over the past week, the price has changed by +2.07%, over one month by -5.76%, over three months by +13.34% and over the past year by -36.74%.
Is RELX a buy, sell or hold?
Relx has received a consensus analysts rating of 4.00.
Therefore, it is recommended to buy RELX.
- StrongBuy: 1
- Buy: 0
- Hold: 1
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the RELX price?
| Analysts Target Price | 52.5 | 54.4% |
Relx (RELX) - Fundamental Data Overview
as of 18 May 2026
Market Cap GBP = 43.05b (57.39b USD * 0.7502 USD.GBP)P/E Trailing = 21.3158
P/E Forward = 17.2712
P/S = 5.9839
P/B = 18.5229
P/EG = 1.3291
Revenue TTM = 18.99b GBP
EBIT TTM = 4.38b GBP
EBITDA TTM = 6.07b GBP
Long Term Debt = 5.63b GBP (from longTermDebt, last quarter)
Short Term Debt = 1.57b GBP (from shortTermDebt, last quarter)
Debt = 7.32b GBP (from shortLongTermDebtTotal, last quarter)
Net Debt = 7.19b GBP (from netDebt column, last quarter)
Enterprise Value = 50.24b GBP (43.05b + Debt 7.32b - CCE 130.8m)
Interest Coverage Ratio = 7.71 (Ebit TTM 4.38b / Interest Expense TTM 568.5m)
EV/FCF = 9.18x (Enterprise Value 50.24b / FCF TTM 5.47b)
FCF Yield = 10.89% (FCF TTM 5.47b / Enterprise Value 50.24b)
FCF Margin = 28.80% (FCF TTM 5.47b / Revenue TTM 18.99b)
Net Margin = 21.02% (Net Income TTM 3.99b / Revenue TTM 18.99b)
Gross Margin = 65.00% ((Revenue TTM 18.99b - Cost of Revenue TTM 6.65b) / Revenue TTM)
Gross Margin QoQ = 63.75% (prev 66.25%)
Tobins Q-Ratio = 3.41 (Enterprise Value 50.24b / Total Assets 14.73b)
Interest Expense / Debt = 1.07% (Interest Expense 78.5m / Debt 7.32b)
Taxrate = 25.09% (365.7m / 1.46b)
NOPAT = 3.28b (EBIT 4.38b * (1 - 25.09%))
Current Ratio = 0.49 (Total Current Assets 2.95b / Total Current Liabilities 5.98b)
Debt / Equity = 3.10 (Debt 7.32b / totalStockholderEquity, last quarter 2.36b)
Debt / EBITDA = 1.18 (Net Debt 7.19b / EBITDA 6.07b)
Debt / FCF = 1.31 (Net Debt 7.19b / FCF TTM 5.47b)
Total Stockholder Equity = 2.81b (last 4 quarters mean from totalStockholderEquity)
RoA = 26.93% (Net Income 3.99b / Total Assets 14.73b)
RoE = 142.1% (Net Income TTM 3.99b / Total Stockholder Equity 2.81b)
RoCE = 51.92% (EBIT 4.38b / Capital Employed (Equity 2.81b + L.T.Debt 5.63b))
RoIC = 33.55% (NOPAT 3.28b / Invested Capital 9.78b)
WACC = 6.64% (E(43.05b)/V(50.37b) * Re(7.63%) + D(7.32b)/V(50.37b) * Rd(1.07%) * (1-Tc(0.25)))
Discount Rate = 7.63% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.92%
Shares (quarterly) Correlation: -89.89 | Cagr: -2.44%
[DCF] Terminal Value 86.18% ; FCFF base≈4.51b ; Y1≈5.57b ; Y5≈9.49b
[DCF] Fair Price = 123.7 (EV 226.21b - Net Debt 7.19b = Equity 219.02b / Shares 1.77b; r=6.64% [WACC]; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 28.41 | EPS CAGR: 0.0% | SUE: 0.0 | # QB: 0
Revenue Correlation: 94.04 | Revenue CAGR: 16.86% | SUE: N/A | # QB: 0
EPS current Year (2026-12-31): EPS=1.94 | Chg30d=+0.65% | Revisions=+14% | GrowthEPS=+11.2% | GrowthRev=+5.8%
EPS next Year (2027-12-31): EPS=2.17 | Chg30d=-0.36% | Revisions=+0% | GrowthEPS=+11.8% | GrowthRev=+6.3%
[Analyst] Revisions Ratio: +14%